Breaking Research News from sources other than Breastcancer.org
Comments
-
Lumpie, thanks for posting this. Noticed that you are a double negative too. Hopefully, identifying these subgroups and outcomes will be included in future treatment studies.
-
A dear family friend works for an organization that has created a running database of PubMed publications. If you look at the home page for PubMed, it says "PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites." That's a lot of links, and they don't database it to make it easier to search.
The database my friend is working on is called meta.org. Here is a page on how it works. You can create customized searches and get notifications of new research posted. You will need to create an account, but it is FREE and always will be.
My first search term (and you can create multiples) is for triple negative breast cancer. Here is part of the page of searches, so you can see what it looks like.
I have just opened my account this week, so I am barely figuring out how to deal with it. Those of you who are even more research oriented than I might have a good time with this.
-
Coolio, thanks, MM!
-
Newly discovered behavior of known chemical compound might lead to breast cancer drugs that keep [ER+] tumors from coming back
...Tamoxifen, and drugs like it, block the ER-alpha receptor, while fulvestrant and similar drugs induce the cell to degrade it. By blocking or degrading the ER-alpha receptor, these anti-hormonal drugs greatly reduce the signal for the cancer cell to grow and reproduce. But, as Prossnitz and his team have previously shown, they also activate GPER, and GPER signals the cell to keep growing and reproducing.
Most breast cancer cells follow the ER-alpha signal and die on schedule when ER-alpha is blocked or degraded. But a very small number of breast cancer cells may follow the GPER signal and survive. And those cells can grow into aggressive tumors that no longer respond to anti-hormonal drugs.
Prossnitz and his team discovered a compound some years ago called AB-1 that binds to ER-alpha but does not activate GPER, thereby avoiding the undesirable side effect of current anti-hormonal drugs. In their Cell Chemical Biology paper, they report their studies that describe AB-1's unique binding and activity behavior.
https://www.newswise.com//articles/discovery-could-lead-to-new-breast-cancer-drugs
-
Genetic study provides most comprehensive map of risk to date of breast cancer risk
A major international study of the genetics of breast cancer has identified more than 350 DNA 'errors' that increase an individual's risk of developing the disease. The scientists involved say these errors may influence as many as 190 genes...
In this new study, researchers from hundreds of institutions worldwide collaborated to compare the DNA of 110,000 breast cancer patients against that of some 90,000 healthy controls. By looking in much closer detail than was previously possibly, they identified 352 risk variants. It is not yet clear exactly how many genes these target, but the researchers have identified 191 genes with reasonable confidence; less than one in five of these had been previously recognised.
https://www.sciencedaily.com/releases/2020/01/200107122305.htm
-
New Compounds Block Master Regulator of Cancer Growth, Metastasis
Scientists have developed new drug compounds that thwart the pro-cancer activity of FOXM1, a transcription factor that regulates the activity of dozens of genes. The new compounds suppress tumor growth in human cells and in mouse models of several types of human breast cancer...
"FOXM1 is a key factor that makes breast cancer and many other cancers more aggressive and more difficult to treat," Benita Katzenellenbogen said. "Because it is a master regulator of cancer growth and metastasis, there has been great interest in developing compounds that would be effective in blocking it."The research is promising, but preliminary, the scientists said. Full development of new anti-cancer drug agents can take more than a decade from this stage of discovery.
https://scitechdaily.com/new-compounds-kill-breast-cancer-cells-and-block-tumor-growth/
-
For those who are HER2+ -- this just appeared in the National Cancer Institute newsletter about two new treatments
https://www.cancer.gov/news-events/cancer-currents...
-
https://www.practiceupdate.com/C/94747/56?elsca1=emc_enews_topic-alert
Re: Clinical and pathological factors influencing risk of late distant recurrence in ER+ ILC
-
Murfy - thank you for the lymphedema post. I will ask the DR. Right now my DR is very hopeful that the Ibrance will knock out the tumor in the axilla causing it, and that no more treatment will be needed. It is on the contraleteral side where lymphnodes removed. Have you heard anything about the success rate of surgery for lymphedema? DR, a surgeon, and lymphatic therapist not confident in surgery approach, not available in my state.
2009 - Left. Lumpectomy, 2 nodes checked, radiation, tamoxifen 5 years
2016 Left, again. Chemo, bi-lateral (my choice), AI initially, switched to tamoxifen (SEs)
2019 - Sweeling in right arm. Scans and biopsy revealed cancer in R- A axilla. Now on Ibrance.
-
Molecule 'selectively killed [triple negative] cancer cells,'
[A] small molecule discovered in animals on the seabed off the coast of Bjørnøya in 2011 [is being investigated for its effects on caner].
The molecule is part of a so-called hydroid – a collection of single cells joined together in a plant-like form and stuck on the seabed. Tests of its impact on multiple cell lines revealed many that were unaffected, but breast cancer cells showed the greatest impact.
The largest impact was the samples against a special type of breast cancer cells including triple-negative breast cancer...
"If it can be developed into a medicine, it will be a completely new treatment alternative for a group of cancer patients who now have limited treatment options," [Kine Østnes Hansen, an associate researcher at UiT Norway's Arctic University] said.
-
Flu vaccines may shrink tumors and boost cancer treatment
-
nice one Marijen
-
-
That is pretty amazing Bev/Jen. It's good for 10 autoimmune diseases and fatty liver. I wonder what the autoimmune diseases are as a lot of us have them.
-
Wow! Thanks for posting!
-
Marijen,
I also wonder if this would be applicable to non-TNBC cancer at some point, since it sure sounds like some kind of wonder drug.
-
another nice one BevJen!
-
Thanks BevJen, I think Leronlimab is also for other types, as CCR5 expression could be observed in many different cancers....
-
How proton radiotherapy can kill cancer in milliseconds
New research in mice shows "for the first time" that scientists can use protons to administer radiation therapy in a matter of milliseconds, killing cancer cells while protecting healthy tissue.
https://www.medicalnewstoday.com/articles/327476.p... -
New Cardiac Abnormalities Following Radiation Therapy in Breast Cancer Patients Treated With Trastuzumab
- "This retrospective study was designed to evaluate imaging abnormalities following modern radiation therapy and trastuzumab for breast cancer. Left-sided radiation was associated with an increase in new cardiac abnormalities. The incidence of new abnormalities correlated with radiation dose exposure." – Neil Majithia, MD
- New cardiac abnormalities appear to be relatively common among patients with breast cancer treated with trastuzumab plus radiation. Further studies are warranted to evaluate the long-term clinical significance of these abnormalities seen on imaging.
-
Molecular Imaging to Identify Patients With Metastatic Breast Cancer Who Benefit From Endocrine Treatment Combined With Cyclin-Dependent Kinase Inhibition
- This study was designed to evaluate the predictive benefit of positron-emission tomography with estrogen-tagged labeling (FES-PET) for 27 patients with ER+ breast cancer treated with letrozole and palbociclib. The median time to progression was 73 weeks in those with 100% FES-positive disease versus 27 weeks in heterogenous FES-positive disease and 15 weeks in those without FES positivity.
- FES-PET may identify patients with ER+ breast cancer who will benefit from the addition of a cyclin-dependent kinase inhibitor to letrozole.
Commentary by Lillie D Shockney RN, BS, MAS, ONN-CGIt is wonderful to see that FES-PET may provide a means of helping to determine which patients with hormone receptor–positive metastatic disease may benefit most from endocrine treatment combined with a CDK-inhibiting drug. The authors discuss the difficulties in obtaining biopsies from metastatic lesions, which can be correct in some cases. A bigger issue, however, is that, in many cases, no attempt is made at all, and treatment remains based on the primary lesion in the breast to determine the prognostic factors of the metastatic lesions, which is a mistake and a violation in the standard of care.
Whatever can be done to make it easier on the patient (biopsies of other organ sites are quite painful) and potentially more accurate in determining the degree of positivity of each metastatic organ site can really go a long way in potentially helping to determine who are the right candidates for this therapy. Those benefiting seem to benefit for a long time, which is wonderful, truly making this disease a chronic illness that is manageable.
-
Things are changing! "Innovators have invented a better way for surgeons to locate tumors during lumpectomies for breast cancer."
-
umakemehappy ...GPS guided surgery. That's really exciting. For surgeons for sure. Interesting reading. Thanks!
-
Inclusion of endogenous plasma dehydroepiandrosterone sulphate and mammographic density in risk prediction models for breast cancer
Marike Gabrielson, Kumari A. Ubhayaseker, Santosh R. Acharya, Mikael Andersson Franko, Mikael Eriksson, Jonas Bergquist, Kamila Czene and Per Hall
DOI: 10.1158/1055-9965.EPI-19-11Abstract
Background Endogenous hormones and mammographic density are risk factors for breast cancer. Joint analyses of the two may improve the ability to identify high-risk women. Methods This study within the KARMA cohort included pre-diagnostic measures of plasma hormone levels of dehydroepiandrosterone (DHEA), its sulphate (DHEAS) and mammographic density in 629 cases and 1,223 controls, not using menopausal hormones. We evaluated the area under the receiver-operating curve (AUC) for risk of breast cancer by adding DHEA, DHEAS, and mammographic density, to the Gail or Tyrer-Cuzick 5-year risk scores or the CAD2Y 2-year risk score. Results DHEAS and percentage density were independently and positively associated with breast cancer risk (P=0.007 and P<0.001, respectively) for postmenopausal, but not premenopausal, women. No significant association was seen for DHEA. In postmenopausal women, those in the highest tertiles of both DHEAS and density were at greatest risk of breast cancer (odds ratio (OR) 3.5; 95% confidence interval (CI) 1.9-6.3) compared to the lowest tertiles. Adding DHEAS significantly improved the AUC for the Gail (+2.1 units, P=0.008) and Tyrer-Cuzick (+1.3 units, P=0.007) risk models. Adding DHEAS to the Gail and Tyrer-Cuzick models already including mammographic density further increased the AUC by 1.2 units, (P=0.006) and 0.4 units (P=0.007), respectively, compared to only including density. Conclusion DHEAS and mammographic density are independent risk factors for breast cancer and improve risk discrimination for postmenopausal breast cancer. Impact Combining DHEAS and mammographic density could help identify women at high risk who may benefit from individualised breast cancer screening and/or preventive measures among postmenopausal women.
- Received September 11, 2019.
- Revision received November 6, 2019.
- Accepted January 10, 2020.
- Copyright ©2020, American Association for Cancer Research.
-
Acid reflux drugs may have negative side effects for breast cancer survivors
New Ohio State University research shows an association between breast cancer survivors' use of proton pump inhibitors (PPIs) and reports of problems with concentration and memory. On average, cognitive problems reported by PPI users were between 20 and 29 percent more severe than issues reported by non-PPI users. PPIs are sold under such brand names as Nexium, Prevacid and Prilosec.
https://www.sciencedaily.com/releases/2020/01/200117110840.htm
Study DOI: 10.1007/s11764-019-00815-4
-
Some happy reading!
Immune cell which kills most cancers discovered by accident by British scientists in major breakthrough
.
-
Interesting article Kanga Roo. From the article it sounds like they plan to start doing human trials maybe in November. I wonder if this is doing well in trials how long we would have to wait before it could be made available...5 to 10 years? I don't know what the timeframes are in the UK for new treatments. Does the UK have the "Right to Try" like the USA now has?
-
I hope we here more about this 'new' immune cell! wow! Exciting!
-
Oh my gosh, billions spent on cancer research and they find this by accident! I hope it lives up to even a fraction of its potential!
-
Dear all, what Kanga_Roo posted... That would be so crazy... I don't know even what to say, and although sounds "too easy and good to be true", CAR-T was just the same genius story, which we have already forgotten - we simply use these therapies today. Let's hope for the best, let's hold on!
Husband Saulius
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team